Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Can Early Postoperative O-(2-18FFluoroethyl)-l-Tyrosine Positron Emission Tomography After Resection of Glioblastoma Predict the Location of Later Tumor Recurrence?

Buchmann N, Gempt J, Ryang YM, Pyka T, Kirschke JS, Meyer B, Ringel F.

World Neurosurg. 2019 Jan;121:e467-e474. doi: 10.1016/j.wneu.2018.09.139. Epub 2018 Sep 27.

PMID:
30267942
2.

(18)F-Fluoroethyl-l-Thyrosine Positron Emission Tomography to Delineate Tumor Residuals After Glioblastoma Resection: A Comparison with Standard Postoperative Magnetic Resonance Imaging.

Buchmann N, Kläsner B, Gempt J, Bauer JS, Pyka T, Delbridge C, Meyer B, Krause BJ, Ringel F.

World Neurosurg. 2016 May;89:420-6. doi: 10.1016/j.wneu.2016.02.032. Epub 2016 Feb 15.

PMID:
26893043
3.

Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy.

Piroth MD, Holy R, Pinkawa M, Stoffels G, Kaiser HJ, Galldiks N, Herzog H, Coenen HH, Eble MJ, Langen KJ.

Radiother Oncol. 2011 May;99(2):218-24. doi: 10.1016/j.radonc.2011.03.006. Epub 2011 Apr 16.

PMID:
21497925
4.

Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.

Bette S, Gempt J, Delbridge C, Kirschke JS, Schlegel J, Foerster S, Huber T, Pyka T, Zimmer C, Meyer B, Ringel F.

World Neurosurg. 2016 May;89:230-9. doi: 10.1016/j.wneu.2016.01.085. Epub 2016 Mar 9.

PMID:
26855307
5.

Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI.

Galldiks N, Langen KJ, Holy R, Pinkawa M, Stoffels G, Nolte KW, Kaiser HJ, Filss CP, Fink GR, Coenen HH, Eble MJ, Piroth MD.

J Nucl Med. 2012 Jul;53(7):1048-57. doi: 10.2967/jnumed.111.098590. Epub 2012 May 29. Erratum in: J Nucl Med. 2013 Oct;54(10):1846.

6.

Correlation of Dynamic O-(2-[18F]Fluoroethyl)-L-Tyrosine Positron Emission Tomography, Conventional Magnetic Resonance Imaging, and Whole-Brain Histopathology in a Pretreated Glioblastoma: A Postmortem Study.

Lohmann P, Piroth MD, Sellhaus B, Weis J, Geisler S, Oros-Peusquens AM, Mohlberg H, Amunts K, Shah NJ, Galldiks N, Langen KJ.

World Neurosurg. 2018 Nov;119:e653-e660. doi: 10.1016/j.wneu.2018.07.232. Epub 2018 Aug 2.

PMID:
30077752
7.

O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma.

Pöpperl G, Goldbrunner R, Gildehaus FJ, Kreth FW, Tanner P, Holtmannspötter M, Tonn JC, Tatsch K.

Eur J Nucl Med Mol Imaging. 2005 Sep;32(9):1018-25. Epub 2005 May 5.

PMID:
15877226
8.

Intraoperative tissue fluorescence using 5-aminolevolinic acid (5-ALA) is more sensitive than contrast MRI or amino acid positron emission tomography ((18)F-FET PET) in glioblastoma surgery.

Roessler K, Becherer A, Donat M, Cejna M, Zachenhofer I.

Neurol Res. 2012 Apr;34(3):314-7. doi: 10.1179/1743132811Y.0000000078. Epub 2012 Mar 1.

PMID:
22449387
9.

Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma.

Hayes AR, Jayamanne D, Hsiao E, Schembri GP, Bailey DL, Roach PJ, Khasraw M, Newey A, Wheeler HR, Back M.

Pract Radiat Oncol. 2018 Jul - Aug;8(4):230-238. doi: 10.1016/j.prro.2018.01.006. Epub 2018 Jan 31.

PMID:
29730279
10.

An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases.

Grosu AL, Astner ST, Riedel E, Nieder C, Wiedenmann N, Heinemann F, Schwaiger M, Molls M, Wester HJ, Weber WA.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1049-58. doi: 10.1016/j.ijrobp.2010.07.002. Epub 2011 May 11.

PMID:
21570201
11.

The positive predictive value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment.

Mehrkens JH, Pöpperl G, Rachinger W, Herms J, Seelos K, Tatsch K, Tonn JC, Kreth FW.

J Neurooncol. 2008 May;88(1):27-35. doi: 10.1007/s11060-008-9526-4. Epub 2008 Jan 23.

PMID:
18217207
12.

Monitoring of radiochemotherapy in patients with glioblastoma using O-(2-¹⁸Fluoroethyl)-L-tyrosine positron emission tomography: is dynamic imaging helpful?

Piroth MD, Liebenstund S, Galldiks N, Stoffels G, Shah NJ, Eble MJ, Coenen HH, Langen KJ.

Mol Imaging. 2013 Sep;12(6):388-95.

PMID:
23981784
13.

Comparison of O-(2-18F-Fluoroethyl)-L-Tyrosine Positron Emission Tomography and Perfusion-Weighted Magnetic Resonance Imaging in the Diagnosis of Patients with Progressive and Recurrent Glioma: A Hybrid Positron Emission Tomography/Magnetic Resonance Study.

Verger A, Filss CP, Lohmann P, Stoffels G, Sabel M, Wittsack HJ, Kops ER, Galldiks N, Fink GR, Shah NJ, Langen KJ.

World Neurosurg. 2018 May;113:e727-e737. doi: 10.1016/j.wneu.2018.02.139. Epub 2018 Mar 3.

PMID:
29510293
14.

Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.

Galldiks N, Rapp M, Stoffels G, Fink GR, Shah NJ, Coenen HH, Sabel M, Langen KJ.

Eur J Nucl Med Mol Imaging. 2013 Jan;40(1):22-33. doi: 10.1007/s00259-012-2251-4. Epub 2012 Sep 29.

PMID:
23053325
15.

Pre-irradiation tumour volumes defined by MRI and dual time-point FET-PET for the prediction of glioblastoma multiforme recurrence: A prospective study.

Harat M, Małkowski B, Makarewicz R.

Radiother Oncol. 2016 Aug;120(2):241-7. doi: 10.1016/j.radonc.2016.06.004. Epub 2016 Jul 1.

PMID:
27378734
16.

Patterns of failure for patients with glioblastoma following O-(2-[18F]fluoroethyl)-L-tyrosine PET- and MRI-guided radiotherapy.

Lundemann M, Costa JC, Law I, Engelholm SA, Muhic A, Poulsen HS, Munck Af Rosenschold P.

Radiother Oncol. 2017 Mar;122(3):380-386. doi: 10.1016/j.radonc.2017.01.002. Epub 2017 Jan 19.

PMID:
28110959
17.

Dynamic O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy.

Ceccon G, Lohmann P, Stoffels G, Judov N, Filss CP, Rapp M, Bauer E, Hamisch C, Ruge MI, Kocher M, Kuchelmeister K, Sellhaus B, Sabel M, Fink GR, Shah NJ, Langen KJ, Galldiks N.

Neuro Oncol. 2017 Feb 1;19(2):281-288. doi: 10.1093/neuonc/now149.

18.

Relapse patterns after radiochemotherapy of glioblastoma with FET PET-guided boost irradiation and simulation to optimize radiation target volume.

Piroth MD, Galldiks N, Pinkawa M, Holy R, Stoffels G, Ermert J, Mottaghy FM, Shah NJ, Langen KJ, Eble MJ.

Radiat Oncol. 2016 Jun 24;11:87. doi: 10.1186/s13014-016-0665-z.

19.

O-(2-[(18)F]fluoroethyl)-L-tyrosine uptake is an independent prognostic determinant in patients with glioma referred for radiation therapy.

Sweeney R, Polat B, Samnick S, Reiners C, Flentje M, Verburg FA.

Ann Nucl Med. 2014 Feb;28(2):154-62. doi: 10.1007/s12149-013-0792-7. Epub 2013 Nov 24.

PMID:
24272067
20.

Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma.

Kebir S, Khurshid Z, Gaertner FC, Essler M, Hattingen E, Fimmers R, Scheffler B, Herrlinger U, Bundschuh RA, Glas M.

Oncotarget. 2017 Jan 31;8(5):8294-8304. doi: 10.18632/oncotarget.14166.

Supplemental Content

Support Center